Inflammatory breast cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 2, 2011, Pages 233-241

  Dushkin, Holly ^a   Cristofanilli, Massimo ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

IBC; Inflammatory breast cancer; Locally advanced breast cancer; Multidisciplinary treatment

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; HUMAN; INFLAMMATORY BREAST CANCER; MASTECTOMY; OVERALL SURVIVAL;

EID: 79951521422     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0018     Document Type: Article

References (54)

1. Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program at the National Cancer Institute. J Natl Cancer Inst 2005;97:966-975. (Pubitemid 41430562)
2. Lee B, Tannenbaum N. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of memorial hospital. Surg Gynecol Obstet 1924;38:580.
3. Haagensen CD. Diseases of the female breast. Trans N Engl Obstet Gynecol Soc 1956;10:141-156.
4. Walshe JM, Swain SM. Clinical aspects of inflammatory breast cancer. Breast Dis 2005;22:35-44. (Pubitemid 44308940)
5. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992;10:1014-1024.
6. Chang S, Parker SL, Pham T, et al. Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program of the National Cancer Institute, 1975-1992. Cancer 1998;82:2366-2372.
7. Greene FL, Page DL, Fleming ID, et al. Breast. In: Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Manual, 6th ed. New York, NY: Springer-Verlag; 2002:255-281.
8. Krishnan C, Moline S, Anders K, Warnke RA. Intravascular ALKpositive anaplastic large cell lymphoma mimicking inflammatory breast cancer. J Clin Oncol 2009;27:2563-2565.
9. Gruber G, Ciriolo M, Altermatt HJ, et al. Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer. Int J Cancer 2004;109:144-148. (Pubitemid 38160675)
10. Paradiso A, Tommasi S, Brandi M, et al. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer 1989;64:1922-1927.
11. Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000;2:423-429.
12. Turpin E, Bieche I, Bertheau P, et al. Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene 2002;21:7593-7597. (Pubitemid 35305587)
13. Gonzalez-Angulo AM, Sneige N, Buzdar AU, et al. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res 2004;10(18 Pt 1):6215-6221. (Pubitemid 39287529)
14. Van Laere SJ, Van den Eynden GG, Van der Auwera, et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat 2006;95:243-255.
15. van Golen KL, Wu ZF, Qiao XT, et al. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000;2:418-425. (Pubitemid 32044787)
16. Kleer CG, Zhang Y, Pan Q, et al. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 2002;21:3172-3180. (Pubitemid 34552242)
17. Singletary SE, Cristofanilli M. Defining the clinical diagnosis of inflammatory breast cancer. Semin Oncol 2008;35:7-10. (Pubitemid 351282390)
18. Chow CK. Imaging in inflammatory breast carcinoma. Breast Dis 2005;22:45-54. (Pubitemid 44308941)
19. Yang WT, Le-Petross HT, Macapinlac H, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 2008;109:417-426. (Pubitemid 351692058)
20. Renz DM, Baltzer PA, Bottcher J, et al. Inflammatory breast carcinoma in magnetic resonance imaging: a comparison with locally advanced breast cancer. Acad Radiol 2008;15:209-221.
21. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007;25:4104-4109. (Pubitemid 47495868)
22. Wahl RL, Siegel BA, Coleman RE, et al. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET study group. J Clin Oncol 2004;22:277-285. (Pubitemid 41095092)
23. Baslaim MM, Bakheet SM, Bakheet R, et al. 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer. World J Surg 2003;27:1099-1104. (Pubitemid 37259988)
24. Carkaci S, Macapinlac HA, Cristofanilli M, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med 2009;50:231-238.
25. Panades M, Olivotto IA, Speers CH, et al. Evolving strategies for inflammatory breast cancer: a population-based survival analysis. Clin Oncol 2005;23:1941-1950. (Pubitemid 46211373)
26. Perez CA, Graham ML, Taylor ME, et al. Management of locally advanced carcinoma of the breast. I. Noninflammatory. Cancer 1994;74(1 Suppl):453-465.
27. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469. (Pubitemid 29075229)
28. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997;40:321-329.
29. Harris EE, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 2003;55:1200-1208. (Pubitemid 36338285)
30. Baldini E, Gardin G, Evangelista G, et al. Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer 2004;5:358-363. (Pubitemid 40109642)
31. Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004;22:4067-4074. (Pubitemid 41185175)
32. Veyret C, Levy C, Chollet P, et al. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer 2006;107:2535-2544. (Pubitemid 44845605)
33. Cristofanilli M, Buzdar AU, Sneige N, et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 2001;92:1775-1782. (Pubitemid 32952495)
34. Guerin M, Gabillot M, Mathieu MC, et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer 1989;43:201-208. (Pubitemid 19062410)
35. Lerebours F, Bertheau P, Bieche I, et al. Evidence of chromosome regions and gene involvement in inflammatory breast cancer. Int J Cancer 2002;102:618-622. (Pubitemid 35334470)
36. Charpin C, Bonnier P, Khouzami A, et al. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Anticancer Res 1992;12:591-597.
37. Sawaki M, Ito Y, Akiyama F, et al. High prevalence of HER-2/ neu and p53 overexpression in inflammatory breast cancer. Breast Cancer 2006;13:172-178.
38. Parton M, Dowsett M, Ashley S, et al. High incidence of HER-2 positivity in inflammatory breast cancer. Breast 2004;13:97-103. (Pubitemid 38443604)
39. Prost S, Le MG, Douc-Rasy S, et al. Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer 1994;58:763-768. (Pubitemid 24306360)
40. Limentani SA, Brufsky AM, Erban JK, et al. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 2007;25:1232-1238. (Pubitemid 46640569)
41. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003;21:46-53.
42. Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006;24:1831-1838. (Pubitemid 46638980)
43. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2- negative cohort. Lancet 2010;375:377-384.
44. Boussen H, Cristofanilli M, Zaks T, et al. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol 2010;28:3248-3255.
45. Van der Auwera I, Van den Eynden GG, Colpaert CG, et al. Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res 2005;11:7637-7642. (Pubitemid 41611604)
46. Shirakawa K, Tsuda H, Heike Y, et al. Absence of endothelial cell, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001;61:445-451. (Pubitemid 32128594)
47. Overmoyer B, Robertson K, Persons M, et al. A phase I pharmokinetic and pharmacodynamic study of SU5416 and doxorubicin (ADR) in inflammatory breast cancer (IBC) [abstract]. J Clin Oncol 2001;20(Suppl 1):Abstract 391.
48. Wedam S, Low J, Yang X, et al. A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inflammatory breast cancer [abstract]. J Clin Oncol 2004;21(Suppl 1):Abstract 578.
49. Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007;9:115-119. (Pubitemid 46332383)
50. Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003;21:2492-2499. (Pubitemid 46606330)
51. Vlastos G, Fornage BD, Mirza NQ, et al. The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. Am J Surg 2000;179:446-452.
52. Curcio LD, Rupp E, Williams WL, et al. Beyond palliative mastectomy in inflammatory breast cancer - a reassessment of margin status. Ann Surg Oncol 1999;6:249-254. (Pubitemid 29221010)
53. Liao Z, Strom EA, Buzdar AU, et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys 2000;47:1191-1200. (Pubitemid 30421171)
54. Woodward WA, Buchholz TA. The role of locoregional therapy in inflammatory breast cancer. Semin Oncol 2008;35:78-86. (Pubitemid 351282389)